EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer

Senna W M Lammers iD, Sandra M E Geurts, Irene E G van Hellemond, Astrid C P Swinkels, Carolien H Smorenburg, Maurice J C van der Sangen, Judith R Kroep, Hiltje de Graaf, Aafke H Honkoop, Frans L G Erdkamp, Wilfred K de Roos, Sabine C Linn iD und 4 weitere

JNCI Cancer Spectrum · 2023

DOI: 10.1093/jncics/pkad092 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JNCI Cancer Spectrum, 2023. Verfasst von Senna W M Lammers und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, Maastricht, the Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity has been associated with an adverse prognosis and reduced efficacy of endocrine therapy in patients with hormone receptor-positive (HR+) breast cancer (BC). This study determines the prognostic and predictive effect of body mass index (BMI) on the disease-free survival (DFS) of postmenopausal HR+ BC patients.

Methods

Patients were identified from the DATA study (NCT00301457), a randomized controlled trial evaluating the efficacy of 6 vs 3 years of anastrozole after 2 to 3 years of adjuvant tamoxifen in postmenopausal women with HR+ BC. Patients were classified as normal weight (BMI: 18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), or obese (≥30.0 kg/m2). The primary endpoint was DFS, evaluated from randomization (prognostic analyses) or 3 years after randomization onwards (predictive analyses; aDFS) using multivariable Cox regression analyses. P-values were 2-sided.

Results

This study included 678 normal weight, 712 overweight, and 391 obese patients. After a median follow-up of 13.1 years, overweight and obesity were identified as negative prognostic factors for DFS (hazard ratio (HR) = 1.16; 95% confidence interval (CI) = 0.97 to 1.38 and HR = 1.26; 95% CI = 1.03 to 1.54, respectively). The adverse prognostic effect of BMI was observed in women aged younger than 60 years, but not in women aged 60 years or older (P-interaction = .009). The effect of extended anastrozole on aDFS was similar in normal weight (HR = 1.00; 95% CI = 0.74 to 1.35), overweight (HR = 0.74; 95% CI = 0.56 to 0.98), and obese patients (HR = 0.97; 95% CI = 0.69 to 1.36) (P-interaction = .24).

Conclusion

In this study among 1781 HR+ BC patients, overweight and obesity were adverse prognostic factors for DFS. BMI did not impact the efficacy of extended anastrozole.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleAnastrozoleBody Mass IndexPrognosisOverweightObesity

Substanzen

Anastrozole

Autor:innen und Institutionen

  • Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, Maastricht, the Netherlands.
  • Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Clinical research department, Netherlands Comprehensive Cancer Organisation (IKNL), Nijmegen, the Netherlands.
  • Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.

ORCID-Profile: Senna W M Lammers, Sabine C Linn, Vivianne C G Tjan-Heijnen

Förderung

  • AstraZeneca

Zitieren

APA

Lammers, S. W. M., Geurts, S. M. E., van Hellemond, I. E. G., Swinkels, A. C. P., Smorenburg, C. H., van der Sangen, M. J. C., Kroep, J. R., de Graaf, H., Honkoop, A. H., Erdkamp, F. L. G., de Roos, W. K., Linn, S. C., Imholz, A. L. T., Smidt, M. L., Vriens, I. J. H., & Tjan-Heijnen, V. C. G. (2023). The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkad092

Vancouver

Lammers SWM, Geurts SME, van Hellemond IEG, Swinkels ACP, Smorenburg CH, van der Sangen MJC, et al. The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. JNCI Cancer Spectrum. 2023. doi:10.1093/jncics/pkad092

BibTeX
@article{Lammers2023,
  author = {Lammers, Senna W M and Geurts, Sandra M E and van Hellemond, Irene E G and Swinkels, Astrid C P and Smorenburg, Carolien H and van der Sangen, Maurice J C and Kroep, Judith R and de Graaf, Hiltje and Honkoop, Aafke H and Erdkamp, Frans L G and de Roos, Wilfred K and Linn, Sabine C and Imholz, Alexander L T and Smidt, Marjolein L and Vriens, Ingeborg J H and Tjan-Heijnen, Vivianne C G},
  title = {The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer},
  journal = {JNCI Cancer Spectrum},
  year = {2023},
  doi = {10.1093/jncics/pkad092}
}
Kostenlos starten →